Company Summary: IGM Biosciences, Inc.

Overview:

• Name: IGM Biosciences, Inc.
• Incorporation: Delaware
• Principal Office: 325 E. Middlefield Road, Mountain View, CA 94043
• Telephone: (650) 965-7873
• Stock Ticker: IGMS (Listed on Nasdaq Global Select Market)
• Securities: Common Stock (par value $0.01)

Business Focus:

• IGM Biosciences is engaged in the development of innovative biopharmaceutical therapies, with an emphasis on antibody engineering and research, particularly within the oncology, autoimmunity, and inflammation fields.
• The Company’s strategic focus appears to be on developing next-generation biotherapeutics, including monoclonal and bispecific antibodies.

Financial and Operational Highlights:

• Market Capitalization: Approximately $50.7 million as of June 28, 2024.
• Shares Outstanding:
  • As of February 28, 2025, there are 34,388,419 shares of common stock and 25,386,983 shares of non-voting common stock outstanding.
• Customers: Not specified.
• Employees: Not specified.
• Revenue & Income: Not specified.
• The company’s financial details, such as specific revenue, net income, or number of customers, are not provided in the excerpt.

Corporate Structure and Governance:

• The Board of Directors consists of nine members with a mix of independent and affiliated directors.
• The company maintains several committees: Audit, Compensation, Corporate Governance & Nominating, and Research & Clinical Development.
• The company emphasizes corporate governance best practices, risk oversight, and independence standards compliant with Nasdaq regulations and SEC rules.

Products and Development:

• IGM Biosciences is primarily a biotechnology research and development company focused on antibody-based therapies; specific product candidates or stages of clinical development are not detailed in the provided text.

Additional Notes:

• The company is classified as a "smaller reporting company" and an "emerging growth company."
• They have a history of issuing equity and warrants associated with private placements and public offerings, with notable transactions in 2023.
• No specific data on revenue, profit, customer base, or employee count is provided in this section.

Summary:
IGM Biosciences, Inc. is a biotechnology company centered on the development of advanced biologic therapeutics, particularly antibody-based drugs. It is publicly traded with a relatively small market cap and a focus on innovation in immunology, oncology, and inflammation. The company’s governance structure and strategic focus on research and clinical development are designed to support its mission to develop next-generation biotherapeutics. No detailed financial metrics or customer and employee figures are disclosed in the provided document.